Novel targeted agents for the treatment of lung cancer in China - Wikidata - awgldk - TriplyDB

Novel targeted agents for the treatment of lung cancer in China

Novel targeted agents for the treatment of lung cancer in China

http://www.wikidata.org/entity/Q26786580

about

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

P2860

Q33876861-F2585C88-58B0-4D19-A10F-20F46303EC1E Q37357699-1FD885F6-64F6-4618-8CFD-DC5005831DC2

P2860

Novel targeted agents for the treatment of lung cancer in China

http://www.wikidata.org/entity/Q26786580

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Novel targeted agents for the treatment of lung cancer in China

@ast

Novel targeted agents for the treatment of lung cancer in China

@en

Novel targeted agents for the treatment of lung cancer in China

@nl

type

label

Novel targeted agents for the treatment of lung cancer in China

@ast

Novel targeted agents for the treatment of lung cancer in China

@en

Novel targeted agents for the treatment of lung cancer in China

@nl

prefLabel

Novel targeted agents for the treatment of lung cancer in China

@ast

Novel targeted agents for the treatment of lung cancer in China

@en

Novel targeted agents for the treatment of lung cancer in China

@nl

P1433

Q26786580-97C27DAC-CF76-42D1-AD61-E9A0F5CA7321

P1476

Q26786580-C2CB02A5-0D17-4261-A6F8-41CAB01F7503

P2093

Q26786580-8056813B-A0EA-4AAA-921B-F332B8D00CC4

Q26786580-B5AF9CB0-AA5A-450D-BEE6-705A2ECCCF06

P2860

Q26786580-0728C7CD-F244-4B9E-90E4-933697B967D4

Q26786580-075807A0-027C-4F04-9866-D53882F4A0B9

Q26786580-0B0FABC8-6F11-4454-9BD3-401C9C265E70

Q26786580-0EC233B1-3581-4453-8458-B88A7BC2855C

Q26786580-136C0806-B604-4C96-8625-1D18665EA3D7

Q26786580-1A15E701-4693-40D3-AB67-BC4323E3DBF7

Q26786580-1A3ED714-FBD9-49D9-B949-B2BA43AFA25A

Q26786580-22C79754-EBB2-487C-A4F4-B7EFDBE92FEF

Q26786580-24C8250A-3534-4858-AA12-83C240ADF3DD

Q26786580-2CF8AC8B-8AE9-4FB4-B9CE-7D1D859F8B39

P304

Q26786580-EC3998B6-F81B-4003-AF93-9EAEC0381A7E

P31

Q26786580-63E5F2DD-5BA5-48F0-A077-A7E831895675

P3181

Q26786580-432FF5AB-1159-4F59-A567-7FC5B5AC0F68

P356

Q26786580-A006EA54-737D-463E-8141-73BC14358677

P407

Q26786580-35AA15DF-C9F3-470B-98CD-F229D3A9F0FD

P478

Q26786580-800828A6-AFFE-4AD1-B1BC-3FAB68854031

P50

Q26786580-6F57F6B3-F7FC-4BAB-8C08-C50522D818FD

P577

Q26786580-00007B0F-337B-4ECA-91E1-ADAF4C4C1789

P698

Q26786580-3E4310F5-4A0B-46CB-B69C-1A2BCC3713E0

P3181

P356

P1433

P1476

Novel targeted agents for the treatment of lung cancer in China

@en

P2093

Si-Yang Liu

http://www.w3.org/2001/XMLSchema#string

Yi-Long Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Review of the current targeted therapies for non-small-cell lung cancer

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

P304

3089-3096

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4796771

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/CNCR.29522

http://www.w3.org/2001/XMLSchema#string

P407

P478

121 Suppl 17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26331815

http://www.w3.org/2001/XMLSchema#string